Compare The Coca-Cola Co K (KO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Novo Nordisk A/S — how do they compare? The Coca-Cola Co K trades at $81.9 (market cap $353.32B), while Novo Nordisk A/S trades at $49.26 (market cap $220.53B). The key difference: The Coca-Cola Co K is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| KO | NVO | |
|---|---|---|
Market Cap | $353.32B | $220.53B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $71.70 |
52-Week Low | $65.67 | $35.29 |
Enterprise Value | $383.39B | $239.49B |
Dividend Yield | 2.58% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $81.56, down 3.96% on the day, with a bearish technical signal but strong fundamentals including a 27.8% net income margin and consistent earnings beats. Recent news highlights institutional accumulation and steady dividend payments. The stock is supported by robust cash flow and brand strength, though near-term price action shows weakness below key resistance.
Outlook remains positive with a consensus price target of $90.67, offering ~11% upside. Risks include regional demand divergence and high debt levels. The stock presents a value opportunity for dividend-focused investors given its 64-year dividend growth streak, but macroeconomic pressures warrant caution.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
